Lancet Oncol. 2026 Nov 10. pii: S1470-2045(26)00337-2. [Epub ahead of print]
Jiajia Li,
Kan Yonemori,
Kaoru Niimi,
Satoshi Nakagawa,
Kosuke Yoshihara,
Shogo Shigeta,
Jianqing Zhu,
Hui Qiu,
Jie Tang,
Hidemichi Watari,
Tatsuyuki Chiyoda,
Shoji Nagao,
Zhiqing Liang,
Yuanguang Meng,
Huimei Zhou,
Ruifang An,
Aikou Okamoto,
Shin Nishio,
Kazuhiro Takehara,
Junzo Hamanishi,
Shuzhong Yao,
Fengxia Xue,
Ge Lou,
Hongming Pan,
Wenjun Cheng,
Rutie Yin,
Wei Duan,
Muneaki Shimada,
Yixiang Zhang,
Yibin Wang,
Fugen Li,
Juan Chen,
Chenxian Dai,
Chao Lv,
Jihong Liu,
Xiaohua Wu.
BACKGROUND: Ovarian clear cell carcinoma is a rare but aggressive and biologically distinct subtype of ovarian cancer, in which PIK3CA mutations are common. Advanced ovarian clear cell carcinoma is very difficult to treat, and after failure of platinum-based chemotherapy, therapeutic options are limited. We aimed to evaluate the anti-tumour activity and safety of the PI3Kα inhibitor, risovalisib, for treatment of patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma.
METHODS: We conducted a single-arm, phase 2 trial of the PI3Kα inhibitor, risovalisib, in 27 centres in China and 12 centres in Japan. Eligible participants were adult patients (aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1) with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma and one to three lines of previous systemic anti-tumour treatment. Risovalisib was given orally at 40 mg daily in 21-day cycles until disease progression, unacceptable toxicity, or other protocol-defined reasons for discontinuation. The primary endpoint was objective response rate assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumours (version 1.1), among all treated patients with a confirmed PIK3CA hotspot mutation and baseline tumour assessments with measurable lesions per BIRC (efficacy analysis set). The primary endpoint was considered met if the lower 95% CI was greater than 8%. Safety analyses were performed in all patients who received at least one dose of risovalisib (safety analysis set). The trial is registered with ClinicalTrials.gov (NCT05043922) and is ongoing but no longer recruiting patients.
FINDINGS: Between Oct 6, 2021, and Jan 31, 2024, 93 patients were enrolled and received risovalisib. The median age was 49 years (IQR 43-58), all patients were female, 52 (56%) were from Japan, 41 (44%) were from China, and 63 (68%) had two or more previous lines of therapy. The median duration of follow-up was 14·5 months (IQR 8·6-18·3). The objective response rate was 29 (35% [95% CI 25-46]) of 84 patients in the efficacy analysis set. The most commonly reported grade 3 or worse treatment-related adverse events in 93 patients were rash (30 [32%]), hyperglycaemia (28 [30%]), and decreased weight (7 [8%]). Treatment-related serious adverse events occurred in 36 (39%) patients, the most common being rash (eight [9%]), pneumonitis (six [6%]), and decreased appetite (four [4%]). There were no treatment-related deaths.
INTERPRETATION: These results support risovalisib as a potential novel treatment option for PIK3CA-mutated ovarian clear cell carcinoma, a rare yet lethal cancer in dire need of additional treatment options. Combination strategies including risovalisib could also be explored to further increase efficacy observed in this study.
FUNDING: Haihe Biopharma.